Kemwell expands analytical services capabilities in India
To support a contract with large multinational pharmaceutical company
Kemwell Biopharma, a global biopharmaceutical contract development and manufacturing company (CDMO) headquartered in Bangalore, India, has expanded its analytical capabilities to service a contract for a large multinational pharmaceutical company.
The CDMO has equipped a new analytical lab in Bangalore with 10 HPLC’s, one UPLC and nine dissolution apparatus and other major analytical instruments and will employ 15 scientists dedicated to this project.
Ninad Deshpanday, President of R&D at Kemwell, said: ‘This project and lab expansion further reflects Kemwell’s commitment to its customers. Kemwell has invested in a dedicated facility to meet the needs of this very important customer. The scope of the project includes method transfer, stability sample analyses and analytical method validation for various projects for the customer. We are actively looking to invest in and grow our development business.’
Kemwell’s R&D division employs more than 100 scientists and provides services ranging from formulation development, analytical development and validation to clinical trial manufacturing.
The team has experience working on early stage development programmes for NCEs, ANDAs, 505(b)(2) and product life cycle management projects for various customers.